

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2; PTPN11)	<p><i>In vitro</i> studies suggest cryptotanshinone could help treat Noonan syndrome and some cancers. Noonan syndrome and other cancers are caused by activating mutations in <i>SHP-2</i>. <i>In vitro</i>, cryptotanshinone directly bound and selectively inhibited SHP-2. In mouse myeloid progenitor cells and human cancer cells expressing <i>SHP-2</i> with an activating mutation, cryptotanshinone inhibited SHP-2-mediated cell signaling and decreased cell growth compared with vehicle. Next steps could include developing analogs for preclinical testing.</p> <p>Aarden Pharmaceuticals Inc.'s SHP-2 inhibitor, IL-B08, is in preclinical testing to treat cancers.</p> <p>SciBX 6(36); doi:10.1038/scibx.2013.991 Published online Sept. 19, 2013</p>	Patent and licensing status unavailable	<p>Liu, W. <i>et al. J. Med. Chem.</i>; published online Aug. 19, 2013; doi:10.1021/jm400474r Contact: Cheng-Kui Qu, Case Western Reserve University, Cleveland, Ohio e-mail: cxq6@case.edu</p>